Skip to main content
Evidence Snapshot

Fatty acid synthase

CHEMBL4158 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:25Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4158
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Fatty acid synthase as ChEMBL target CHEMBL4158, mapped to UniProt P49327. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Fatty acid synthase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4158
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P49327
Fatty acid synthase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Fatty acid synthase matters

As of 2026-09-13

Fatty acid synthase is reviewed as Fatty acid synthase (UniProt P49327); the current evidence base includes 10 approved drugs, 2479 compounds, and 140 assays, with lead potency reaching pChEMBL 8.5.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 10 approved drugs, 2479 compounds, and 140 assays for this target. The dominant activity type is IC50. CHEMBL3623457 is the current potency anchor at pChEMBL 8.5.

Use CHEMBL3623457 as the tractability anchor when discussing potency (pChEMBL 8.5).

Activity source · ChEMBL 36 via Core Engine
10 approved pChEMBL 8.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Fatty acid synthase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P49327, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2479
Total Compounds
140
Total Assays
10
Approved Drugs
IC50: 3926.0, KI: 21.0, KD: 2.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3623457
 8.5 IC50 —
No preferred name
CHEMBL3646811
 8.5 IC50 —
No preferred name
CHEMBL3646807
 8.3 IC50 —
No preferred name
CHEMBL3962197
 8.3 IC50 —
No preferred name
CHEMBL2147033
 8.2 IC50 —

Approved Drugs

Structure Compound First Approval
ORLISTAT
CHEMBL175247
 1998
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:25Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4158